Comparison of Ambulatory Care Access and Quality for Beneficiaries With Disabilities Covered by Medicare Advantage vs Traditional Medicare Insurance.
Journal
JAMA health forum
ISSN: 2689-0186
Titre abrégé: JAMA Health Forum
Pays: United States
ID NLM: 101769500
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
02
09
2021
accepted:
11
11
2021
entrez:
17
8
2022
pubmed:
18
8
2022
medline:
18
8
2022
Statut:
epublish
Résumé
Medicare beneficiaries with disabilities aged 18 to 64 years face barriers accessing ambulatory care. Past studies comparing Medicare Advantage (MA) with traditional Medicare (TM) have not assessed how well these programs meet the needs of beneficiaries with disabilities. To compare differences in enrollment rates, ambulatory care access, and ambulatory care quality for beneficiaries with disabilities in MA vs TM. This cohort study included a nationally representative, weighted sample of 7201 person-years for beneficiaries aged 18 to 64 years with disability entitlement in the Medicare Current Beneficiary Survey from 2015 through 2018. Differences in program enrollment and in measures of access and quality by program enrollment were compared after adjusting for demographic, insurance, social, health, and area characteristics and after reweighting the sample by propensity to enroll in MA as estimated by observed confounders. Data analyses were conducted between November 1, 2020, and November 11, 2021. Medicare Advantage vs TM program enrollment. Six patient-reported measures of ambulatory care access (usual source of care, primary care usual source of care, specialist visit) and quality (cholesterol screening, influenza vaccination, colon cancer screening). The mean (SD) age of the overall study population was 52.1 (11.0) years; 49.5% were female and 50.5% were male; 1.6% were Asian/Pacific Islander; 17.4%, Black; 10.2% Hispanic; 1.4%, Native American; 65.1%, White, and 4.2%, multiracial. Among all beneficiaries living in the community, individuals with disability entitlement were less likely to enroll in MA than other beneficiaries (34.8% vs 41.2%). The final sample of beneficiaries with disabilities included 2444 person-years in MA and 4757 person-years in TM. Beneficiaries with disabilities in MA vs TM were more likely to be of a minority race or ethnicity (35.7% vs 27.6%) and less likely to be enrolled in private insurance (11.9% vs 25.0%). Comparing MA with TM among beneficiaries with disabilities, those in MA had significantly better rates of access to a usual source of care (90.2% vs 84.9%; adjusted propensity-weighted marginal difference [APWMD], 2.9%; 95% CI, 0.2%-5.7%), access to specialist visits (53.2% vs 44.8%; APWMD, 5.5%; 95% CI, 0.6%-10.5%), cholesterol screenings (91.1% vs 86.4%; APWMD, 3.8%; 95% CI, 0.9%-6.7%), influenza vaccinations (61.4% vs 51.5%; APWMD, 10.4%; 95% CI, 5.3%-15.5%), and colon cancer screenings (68.4% vs 54.6%; APWMD, 10.3%; 95% CI, 4.8%-15.8%). In this cohort study, Medicare beneficiaries with disabilities were enrolled in MA at significantly lower rates than those without disabilities. However, MA was associated with significantly better ambulatory care access and quality for these beneficiaries on 5 of 6 measures compared with TM.
Identifiants
pubmed: 35977235
doi: 10.1001/jamahealthforum.2021.4562
pii: aoi210076
pmc: PMC8903104
doi:
Substances chimiques
Cholesterol
97C5T2UQ7J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
e214562Informations de copyright
Copyright 2022 Johnston KJ et al. JAMA Health Forum.
Déclaration de conflit d'intérêts
Conflict of Interest Disclosures: Dr Johnston reported receiving funding from the National Institute of Mental Health (R01MH125820) and the National Institute on Aging (R21AG065526). Drs Pollack reported being coguardian of an adult with intellectual disabilities who is dually eligible for Medicare and Medicaid services and thus affected by the policies studied in this work. No other disclosures were reported.
Références
Medicare Medicaid Res Rev. 2014 Jul 17;4(2):
pubmed: 25068076
JAMA Netw Open. 2020 Mar 2;3(3):e201809
pubmed: 32227181
Arch Intern Med. 2003 Sep 22;163(17):2085-92
pubmed: 14504123
Disabil Health J. 2013 Apr;6(2):95-9
pubmed: 23507159
Health Aff (Millwood). 2021 Jun;40(6):910-919
pubmed: 34097512
Health Aff (Millwood). 2010 Sep;29(9):1725-33
pubmed: 20705670
Health Aff (Millwood). 2019 May;38(5):782-787
pubmed: 31059373
Med Care. 2020 Nov;58(11):1004-1012
pubmed: 32925471
JAMA Cardiol. 2019 Mar 1;4(3):265-271
pubmed: 30785590
Med Care Res Rev. 2022 Apr;79(2):207-217
pubmed: 34075825
JAMA. 2021 Aug 17;326(7):628-636
pubmed: 34402828
Med Care. 2014 Dec;52(12):1042-9
pubmed: 25334053
Arch Phys Med Rehabil. 2019 Feb;100(2):289-299
pubmed: 30316959
PLoS Med. 2007 Oct 16;4(10):e297
pubmed: 17941715
Health Serv Res. 2016 Dec;51(6):2176-2205
pubmed: 27891605
Med Care Res Rev. 2017 Dec;74(6):736-749
pubmed: 27516452
Circulation. 2019 Jun 18;139(25):e1082-e1143
pubmed: 30586774
Health Serv Res. 2017 Dec;52(6):2038-2060
pubmed: 29130269
Am Econ J Appl Econ. 2019 Apr;11(2):302-332
pubmed: 31131073
Am J Public Health. 2019 Jan;109(S1):S16-S20
pubmed: 30699025
Expert Rev Pharmacoecon Outcomes Res. 2006 Jun;6(3):261-73
pubmed: 20528520
Health Aff (Millwood). 2012 Dec;31(12):2609-17
pubmed: 23213144
Health Aff (Millwood). 2021 Jun;40(6):937-944
pubmed: 34097516
BMC Health Serv Res. 2017 Mar 29;17(1):241
pubmed: 28356149
Health Aff (Millwood). 2015 Oct;34(10):1675-81
pubmed: 26438743
J Gen Intern Med. 2020 Dec;35(12):3671-3674
pubmed: 32462570
Health Aff (Millwood). 2009 Jan-Feb;28(1):136-46
pubmed: 19124863
JAMA Intern Med. 2019 Apr 1;179(4):524-532
pubmed: 30801625
Health Econ. 2021 Feb;30(2):311-327
pubmed: 33219715
Health Aff (Millwood). 2019 Dec;38(12):1993-2002
pubmed: 31794307
Health Aff (Millwood). 2013 Jul;32(7):1228-35
pubmed: 23836738
Am J Manag Care. 2016 Feb 01;22(2):e53-9
pubmed: 26881320
JAMA. 2021 May 18;325(19):1965-1977
pubmed: 34003218